A mutant strain Cbg61-T37, a co-expression strain Cbg61-T37-MPR1 and a construction method and application thereof
By using gene recombination and ARTP mutagenesis to screen mutant strain Cbg61-T37 and co-expression strain Cbg61-T37-MPR1, the problems of poor stability and high purification cost of β-glucosidase were solved, and the efficient and economical biosynthesis of rare ginsenoside CK was achieved.
Patent Information
- Application Number
- CN202511390897.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-26
- Publication Date
- 2026-06-23
- Estimated Expiration
- 2045-09-26
AI Technical Summary
In the prior art, β-glucosidase (SS-bgly) derived from Sulfolobus solfataricus has poor stability in complex reaction systems, resulting in low synthesis efficiency of rare ginsenoside CK. In addition, the high cost of intracellular enzyme purification and recovery limits its application in large-scale biomanufacturing.
The mutant strain Cbg61-T37 was obtained through gene recombination and ARTP mutagenesis screening, and a co-expression strain Cbg61-T37-MPR1 was constructed. β-glucosidase was immobilized using cell surface display technology, and N-acetyltransferase MPR1 gene was modified to optimize fermentation conditions and improve enzyme stability and catalytic efficiency.
It significantly improves enzyme stability and catalytic efficiency, reduces production costs, and significantly increases the yield and conversion rate of rare ginsenoside CK. The catalyst has good reusability and is suitable for large-scale economic production.